Developer docs
API playgroundTry for free, no card

Search company profiles

IDT Australia

Full company profile

uuid003hge7

Namestring
IDT Australia
Legal namestring
IDT Australia
Company typeenum
Public
Founded yearint
1974
Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
51–100
akta.pro rankint
HeadquartersBoronia, Australia
HQ citystring
Boronia
HQ countrystring
Australia
HQ regionstring
Oceania
Markets served

Serves global market

Offices1 record

Each record includes

City, Country, Type, Description, Source

Keyword5 values
contract pharmaceutical manufacturing, API development services, sterile fill finish, radiopharmaceutical manufacturing, pharmaceutical formulation services
Industry4 codes
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine
NAICS code3 codes
  • Pharmaceutical Preparation Manufacturing325412
  • Pharmaceutical and Medicine Manufacturing3254
  • Scientific Research and Development Services5417
SIC code2 codes
  • Pharmaceutical Preparations2834
  • Services-Commercial Physical & Biological Research8731
Product category
Pharmaceutical Contract Manufacturing (CDMO)
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Contract Manufacturing Services
TypeProfessional Services
Description

Contract development and manufacturing organization (CDMO) providing fee-for-service pharmaceutical development and manufacturing solutions across pre-clinical, clinical, and commercial stages.

idtaus.com.au
2Regulatory Services
TypeLicensing Royalties
Description

Regulatory support services enabling pharmaceutical partners to commercialize products with FDA, TGA, and APVMA regulatory approvals.

idtaus.com.au
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components6 values
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure
Pricing details1 tier
1Project-based custom pricing for pharmaceutical development and manufacturing services
ModelOtherBilling cadenceMulti-year contract
Notes

Custom project-based pricing depending on development stage, product type, and manufacturing scale requirements

idtaus.com.au
GTM typeB2B
B2B
Offering typeServices
Services
Core offering1 text field

IDT Australia is a Contract Development and Manufacturing Organization (CDMO) that produces active pharmaceutical ingredients (APIs), formulates specialty oral dosage forms including Schedule 8 and 9 controlled drugs, and manufactures advanced therapies such as sterile fill-finish products, lyophilised injectables, mRNA therapeutics, and radiopharmaceuticals. Services span pre-clinical through commercial stages and include R&D, analytical and microbiological testing, ICH stability testing, labelling and packaging, project management, supply chain and distribution, and regulatory support.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 value
  • R&D Tax Incentive offering up to 43.5% refundable cash benefit for eligible projects
Product overview1 text field

IDT Australia operates as a Contract Development and Manufacturing Organization (CDMO) offering end-to-end cGMP pharmaceutical manufacturing solutions. The portfolio comprises Active Pharmaceutical Ingredients (APIs) services including small molecule and cytotoxic compound manufacturing, Specialty Orals covering tablets, capsules, and liquid formulations, and Advanced Therapies including Sterile Fill and Finish, mRNA, and Radiopharma services. These core capabilities are supported by Integrated Services encompassing R&D, analytical testing, ICH stability testing, labelling and packaging, project management, supply chain, and regulatory support. The company trades on ASX under ticker IDT:IDT.

Product and service7 records
1Active Pharmaceutical Ingredients (APIs)
CategoryContract API Manufacturing
Description

Contract development and manufacturing of small molecule APIs, including highly potent and cytotoxic compounds, from pre-clinical through commercial scale, plus linker-payload manufacturing for antibody-drug conjugates (ADCs). Offered to pharmaceutical and biotech partners requiring cGMP API supply.

2Specialty Orals
CategoryContract Oral Dosage Manufacturing
Description

Contract formulation and production of solid oral dosage forms including tablets and capsules, non-sterile liquid products, and Schedule 8 and Schedule 9 controlled drug products. Offered to pharmaceutical and biotech partners requiring cGMP oral solid dose manufacturing.

3Sterile Fill and Finish
CategoryContract Sterile Manufacturing
Description

Advanced sterile manufacturing service providing aseptic fill and finish of injectable medicines into vials, supporting partners requiring cGMP sterile injectable production.

4Radiopharma Manufacturing
CategoryContract Radiopharmaceutical Manufacturing
Description

Contract radiopharmaceutical manufacturing service for diagnostic and therapeutic applications, available to advanced therapy developers needing specialised radiopharma production.

5mRNA Manufacturing Services
CategoryContract mRNA Manufacturing
Description

Contract manufacturing capability for mRNA-based therapeutics and vaccines, provided to pharmaceutical and biotech clients developing mRNA medicines.

6Advanced Therapies Manufacturing
CategoryContract Advanced Therapy Manufacturing
Description

Integrated advanced therapy manufacturing service combining advanced sterile fill and finish into vials, lyophilisation (freeze-drying), and radiopharmaceutical manufacturing for partners developing advanced therapeutic products.

7Integrated Services
CategoryIntegrated CDMO Support Services
Description

End-to-end CDMO support services covering Research and Development, Analytical and Microbiological testing, ICH Stability testing, Labelling and Packaging, Project Management, Supply Chain and Distribution, and Regulatory support for pharmaceutical and biotech clients across pre-clinical, clinical, and commercial stages.

Scale indicator3 records

Each record includes

Type, Value, Description, Source

Partnership1 partner
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2025-07-17
Description

Gelteq Limited has partnered with IDT Australia through a memorandum of understanding to establish a dedicated, locally-based manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. The partnership leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise, including FDA, TGA, and APVMA regulatory capabilities, to support Gelteq's product scale-up. The agreement aims to accelerate product development and enable rapid expansion of manufacturing capacity for global markets.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight5 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Full-service CDMO with strong capabilities in highly potent APIs, peptide manufacturing, and sterile fill-finish — closely comparable to IDT's cytotoxic, ADC linker-payload, and controlled-substance specialisations.

2Recipharm
TypeDirect peer
Description

European CDMO focused on small-molecule API manufacturing, sterile fill-finish, and oral dosage forms — directly overlapping with IDT's core service portfolio across multiple modalities.

TypeEmerging player
Description

Contract research and manufacturing organisation providing clinical development and commercial services to biopharma. Partial overlap with IDT through its clinical-stage manufacturing and packaging service line.

TypeDirect peer
Description

Global CDMO providing integrated clinical and commercial manufacturing, packaging, and supply chain services. Comparable in the integrated CDMO plus packaging/labelling positioning that IDT markets.

TypeDirect peer
Description

Global biopharmaceutical CDMO with capabilities across microbial and mammalian biologics, as well as gene therapy and fill-finish. Comparable as a contract manufacturer serving pharma and biotech developers with cGMP capabilities.

TypeDirect peer
Description

One of the largest global CDMOs offering integrated development, manufacturing, and packaging across small molecules, biologics, and advanced therapies. Directly comparable to IDT in end-to-end CDMO positioning, though at substantially greater scale.

TypeBroad incumbent
Description

Through its Patheon business, Thermo Fisher offers one of the broadest CDMO service portfolios globally. Operates broadly across drug substance, drug product, and clinical services — overlapping significantly with IDT but as part of a much larger life sciences platform.

TypeDirect peer
Description

Swiss-based global CDMO leader with capabilities spanning APIs (small and large molecule), fill-finish, and advanced therapies. Comparable business model and customer base to IDT, but with global multi-site capacity that IDT cannot match.

TypeRegional player
Description

Australian-headquartered specialty pharmaceutical company with capabilities in complex oral and injectable generics manufacturing. Comparable regional CDMO/manufacturing exposure serving similar therapeutic categories to IDT within the Australian market.

TypeDirect peer
Description

Asia-Pacific-focused CDMO with capabilities in small-molecule oral solids, sterile injectables, and complex formulations. Comparable as a mid-sized, regionally anchored CDMO competing for similar contract manufacturing work as IDT.

Market position
Strengths4 records

Each record includes

Headline, Details, Source

Weaknesses4 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers2 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment3 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile3 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature4 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
Compliance4 records

Each record includes

Name, Class, Description

Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

IDT Australia

Pharmaceutical Contract Manufacturing (CDMO)en.idtaus.com.au

IDT Australia firmographics

Firmographics
Name
IDT Australia
Legal name
IDT Australia
Website
https://en.idtaus.com.au
Company type
Public
Founded year
1974
Operating status
Operating
Headcount range
51–100 employees
Ownership category
akta.pro rank

IDT Australia industry classification

Industry
Product category
Pharmaceutical Contract Manufacturing (CDMO)
NAICS
Pharmaceutical Preparation Manufacturing (325412), Pharmaceutical and Medicine Manufacturing (3254), Scientific Research and Development Services (5417)
SIC
Pharmaceutical Preparations (2834), Services-Commercial Physical & Biological Research (8731)
akta.pro industry
PRIMARYHLAGABAG
Drug Substance–Drug Product Integrated CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAA
Small-Molecule API & Intermediates CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAGABAH
Sterile Fill-Finish & Aseptic Manufacturing CDMO
Healthcare & Life Sciences/Life Science Tools & Services (CRO/CDMO/Lab Services)/Contract Development & Manufacturing Organizations (CDMO)
SECONDARYHLAIAGAF
Radiopharmaceutical CDMO & Manufacturing (GMP Fill-Finish)
Healthcare & Life Sciences/Pharmaceuticals/Radiopharmaceuticals & Nuclear Medicine

Keywords

  • Contract pharmaceutical manufacturing
  • API development services
  • Sterile fill finish
  • Radiopharmaceutical manufacturing
  • Pharmaceutical formulation services

Where IDT Australia is headquartered

Location

Headquarters

HQ city
Boronia
HQ country
Australia
HQ region
Oceania

Offices1 record

Markets served

IDT Australia business model

Business model
GTM type
B2B
Offering type
Services
Cost components
Personnel, Operations, Technology or R&D, Supply Chain, Marketing or Sales, Infrastructure

Revenue model

  1. Contract Manufacturing Services: Contract development and manufacturing organization (CDMO) providing fee-for-service pharmaceutical development and manufacturing solutions across pre-clinical, clinical, and commercial stages.
  2. Regulatory Services: Regulatory support services enabling pharmaceutical partners to commercialize products with FDA, TGA, and APVMA regulatory approvals.

Pricing tiers

ModelBillingPrice
OtherMulti-year contractProject-based custom pricing for pharmaceutical development and manufacturing services

Go-to-market motion1 record

Distribution channels2 records

Marketing channels4 records

IDT Australia product offering

Product offering

Core offering

IDT Australia is a Contract Development and Manufacturing Organization (CDMO) that produces active pharmaceutical ingredients (APIs), formulates specialty oral dosage forms including Schedule 8 and 9 controlled drugs, and manufactures advanced therapies such as sterile fill-finish products, lyophilised injectables, mRNA therapeutics, and radiopharmaceuticals. Services span pre-clinical through commercial stages and include R&D, analytical and microbiological testing, ICH stability testing, labelling and packaging, project management, supply chain and distribution, and regulatory support.

Product overview

IDT Australia operates as a Contract Development and Manufacturing Organization (CDMO) offering end-to-end cGMP pharmaceutical manufacturing solutions. The portfolio comprises Active Pharmaceutical Ingredients (APIs) services including small molecule and cytotoxic compound manufacturing, Specialty Orals covering tablets, capsules, and liquid formulations, and Advanced Therapies including Sterile Fill and Finish, mRNA, and Radiopharma services. These core capabilities are supported by Integrated Services encompassing R&D, analytical testing, ICH stability testing, labelling and packaging, project management, supply chain, and regulatory support. The company trades on ASX under ticker IDT:IDT.

Differentiator

Problem solved

Functional benefit

Products and services

  • Active Pharmaceutical Ingredients (APIs) Contract development and manufacturing of small molecule APIs, including highly potent and cytotoxic compounds, from pre-clinical through commercial scale, plus linker-payload manufacturing for antibody-drug conjugates (ADCs). Offered to pharmaceutical and biotech partners requiring cGMP API supply.
  • Specialty Orals Contract formulation and production of solid oral dosage forms including tablets and capsules, non-sterile liquid products, and Schedule 8 and Schedule 9 controlled drug products. Offered to pharmaceutical and biotech partners requiring cGMP oral solid dose manufacturing.
  • Sterile Fill and Finish Advanced sterile manufacturing service providing aseptic fill and finish of injectable medicines into vials, supporting partners requiring cGMP sterile injectable production.
  • Radiopharma Manufacturing Contract radiopharmaceutical manufacturing service for diagnostic and therapeutic applications, available to advanced therapy developers needing specialised radiopharma production.
  • mRNA Manufacturing Services Contract manufacturing capability for mRNA-based therapeutics and vaccines, provided to pharmaceutical and biotech clients developing mRNA medicines.
  • Advanced Therapies Manufacturing Integrated advanced therapy manufacturing service combining advanced sterile fill and finish into vials, lyophilisation (freeze-drying), and radiopharmaceutical manufacturing for partners developing advanced therapeutic products.
  • Integrated Services End-to-end CDMO support services covering Research and Development, Analytical and Microbiological testing, ICH Stability testing, Labelling and Packaging, Project Management, Supply Chain and Distribution, and Regulatory support for pharmaceutical and biotech clients across pre-clinical, clinical, and commercial stages.

Quantifiable outcome

  • R&D Tax Incentive offering up to 43.5% refundable cash benefit for eligible projects

Companies that use IDT Australia

Customer profile

Named customers2 records

Segments3 records

Ideal customer profiles3 records

IDT Australia technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature4 records

IDT Australia partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Gelteq LimitedcoreStrategic or Co-development Partner · 17 July 2025Gelteq Limited has partnered with IDT Australia through a memorandum of understanding to establish a dedicated, locally-based manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. The partnership leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise, including FDA, TGA, and APVMA regulatory capabilities, to support Gelteq's product scale-up. The agreement aims to accelerate product development and enable rapid expansion of manufacturing capacity for global markets.

Scale indicators3 records

Recent moves5 records

Expansion highlights5 records

IDT Australia competitors and assessment

Company assessment

Direct peers

  • Corden Pharma: Full-service CDMO with strong capabilities in highly potent APIs, peptide manufacturing, and sterile fill-finish — closely comparable to IDT's cytotoxic, ADC linker-payload, and controlled-substance specialisations.
  • Recipharm: European CDMO focused on small-molecule API manufacturing, sterile fill-finish, and oral dosage forms — directly overlapping with IDT's core service portfolio across multiple modalities.
  • PCI Pharma Services: Global CDMO providing integrated clinical and commercial manufacturing, packaging, and supply chain services. Comparable in the integrated CDMO plus packaging/labelling positioning that IDT markets.
  • AGC Biologics: Global biopharmaceutical CDMO with capabilities across microbial and mammalian biologics, as well as gene therapy and fill-finish. Comparable as a contract manufacturer serving pharma and biotech developers with cGMP capabilities.
  • Catalent: One of the largest global CDMOs offering integrated development, manufacturing, and packaging across small molecules, biologics, and advanced therapies. Directly comparable to IDT in end-to-end CDMO positioning, though at substantially greater scale.
  • Lonza Group: Swiss-based global CDMO leader with capabilities spanning APIs (small and large molecule), fill-finish, and advanced therapies. Comparable business model and customer base to IDT, but with global multi-site capacity that IDT cannot match.
  • Bora Pharmaceuticals: Asia-Pacific-focused CDMO with capabilities in small-molecule oral solids, sterile injectables, and complex formulations. Comparable as a mid-sized, regionally anchored CDMO competing for similar contract manufacturing work as IDT.

Emerging players

  • Syneos Health: Contract research and manufacturing organisation providing clinical development and commercial services to biopharma. Partial overlap with IDT through its clinical-stage manufacturing and packaging service line.

Broad incumbents

  • Thermo Fisher Scientific (Patheon): Through its Patheon business, Thermo Fisher offers one of the broadest CDMO service portfolios globally. Operates broadly across drug substance, drug product, and clinical services — overlapping significantly with IDT but as part of a much larger life sciences platform.

Regional players

  • Mayne Pharma: Australian-headquartered specialty pharmaceutical company with capabilities in complex oral and injectable generics manufacturing. Comparable regional CDMO/manufacturing exposure serving similar therapeutic categories to IDT within the Australian market.

Market position

Strengths4 records

Weaknesses4 records

Competitive moat5 records

Key risks5 records

Key highlights6 records

Customer concentration

IDT Australia social profiles

Digital presence

IDT Australia compliance and trust

Trust signal

Compliance4 records

IDT Australia financial estimates

Financial estimate

Revenue estimate

Valuation estimate

IDT Australia leadership team

Management profile

Number of profiles

IDT Australia funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

IDT Australia M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about IDT Australia

What does IDT Australia do?

IDT Australia is a Contract Development and Manufacturing Organization (CDMO) that produces active pharmaceutical ingredients (APIs), formulates specialty oral dosage forms including Schedule 8 and 9 controlled drugs, and manufactures advanced therapies such as sterile fill-finish products, lyophilised injectables, mRNA therapeutics, and radiopharmaceuticals. Services span pre-clinical through commercial stages and include R&D, analytical and microbiological testing, ICH stability testing, labelling and packaging, project management, supply chain and distribution, and regulatory support.

Is IDT Australia a public or private company?

IDT Australia is a public company. It is classified as public and is currently operating.

When was IDT Australia founded?

IDT Australia was founded in 1974. It employs 51 to 100 people.

Where is IDT Australia based?

IDT Australia is headquartered in Boronia, Australia, in the Oceania region.

How does IDT Australia make money?

Two revenue lines are on record. Contract Manufacturing Services are the primary driver. The others are regulatory Services.

Who are IDT Australia's main competitors?

Direct peers on record are Corden Pharma, Recipharm, PCI Pharma Services, AGC Biologics, Catalent, Lonza Group and Bora Pharmaceuticals. Syneos Health is listed as an emerging player. Thermo Fisher Scientific (Patheon) is listed as a broad incumbent. Mayne Pharma is listed as a regional player.

Does IDT Australia have an API?

No public API is recorded for IDT Australia.

What industry is IDT Australia in?

IDT Australia's product category is Pharmaceutical Contract Manufacturing (CDMO). Its primary akta.pro industry code is HLAGABAG, Drug Substance–Drug Product Integrated CDMO, with a secondary code of HLAGABAA, Small-Molecule API & Intermediates CDMO. Its NAICS code is 325412 and its SIC code is 2834.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
TradingViewIDT Australia Forecasting Positive FY27 Operating Earnings After Strategic ResetIDT Australia forecasts positive operating earnings in FY27, with revenue of $19-20m and EBITDA of $1-1.5m. The forecast follows a strategic reset targeting higher-value pharmaceutical contracts and a $7m manufacturing investment. The company aims to lift annual revenue to $50m within three years.GlobeNewswireGelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing FacilitiesGelteq announced a memorandum of understanding with IDT Australia to build a dedicated manufacturing facility for its gel-based products. The partnership aims to accelerate scale-up across pharmaceutical, nutraceutical, and animal health markets, leveraging IDT's 50+ years of contract manufacturing expertise.Stock TitanGelteq Partners With IDT Australia for Global Pharmaceutical Manufacturing FacilityGelteq announced a memorandum of understanding with IDT Australia for a dedicated manufacturing facility to support its gel-based oral delivery platform. The partnership aims to accelerate scale-up and commercialization across pharmaceutical, nutraceutical, and animal health markets. IDT brings over 50 years of pharmaceutical development and cGMP manufacturing expertise.The Manila TimesGelteq Announces Agreement with IDT Australia to Secure Dedicated New Product Development and Manufacturing FacilitiesGelteq announced a memorandum of understanding with IDT Australia for a dedicated manufacturing facility to support its gel-based oral delivery platform. The partnership aims to accelerate scale-up across pharmaceutical, nutraceutical, and animal health markets, with IDT providing cGMP manufacturing and regulatory expertise.AInvestGelteq's Strategic Manufacturing Partnership with IDT Australia: A Catalyst for Scalable Gel-Based Drug Delivery InnovationGelteq signed a memorandum of understanding with IDT Australia to establish a gel-based drug delivery manufacturing hub in Boronia, Victoria. The partnership aims to bypass costly facility construction and accelerate commercialization, targeting a $13.43B gel delivery market by 2030. The company's financials show a net loss of $3.20 million in Q2 2025.AInvestGelteq Partners with IDT Australia to Establish Dedicated Manufacturing Facility for Gel-Based Products.Gelteq announced a partnership with IDT Australia to establish a dedicated manufacturing facility in Australia for its gel-based products. The purpose-built facility will meet regulatory requirements for therapeutic, veterinary, and nutraceutical markets, leveraging IDT's 50+ years of pharmaceutical manufacturing experience. The collaboration aims to accelerate global scaling and reduce time-to-market.NasdaqGelteq Limited Partners with IDT Australia to Establish Local Manufacturing Facility for Gel-Based ProductsGelteq Limited has entered into a memorandum of understanding with IDT Australia to establish a dedicated, locally-based manufacturing facility for gel-based pharmaceutical, nutraceutical, and animal health products. The partnership leverages IDT's more than 50 years of pharmaceutical development and cGMP manufacturing expertise, including FDA, TGA, and APVMA regulatory capabilities, to support Gelteq's product scale-up. The agreement is aimed at accelerating product development and enabling rapid expansion of manufacturing capacity for global markets.NasdaqASX Cannabis Stocks: 10 Biggest Companies in 2024The article profiles the 10 largest ASX-listed cannabis companies by market cap as of September 3, 2024, including Botanix Pharmaceuticals, Neurotech, and IDT Australia. It details each company's focus, such as medical cannabis products, clinical trials, and revenue figures, with Botanix leading at AU$751.17 million.NasdaqASX Cannabis Stocks: 10 Biggest CompaniesThe article profiles the 10 largest ASX-listed cannabis companies by market cap, including Botanix Pharmaceuticals, Vitura Health, and IDT Australia. It notes the Australian medical cannabis market grew 72% to AU$400 million in the first half of 2024, with Grandview Research forecasting 33.6% annual growth through 2030.PRLogVaccine CDMO Market Booming Worldwide with Key Players - Lonza, Catalent, Patheon, IDTThe global vaccine CDMO market is projected to grow at 8-10% annually, reaching about $5 billion by 2025. Growth is driven by biotech demand and pharma outsourcing, with revenue from commercial manufacturing and volumes from emerging countries, though value comes from North America and Europe.